RUNX1 and acute myeloid leukemia: While significant controversy exists regarding whether older adults benefit from intensive versus low‐intensity chemotherapy [53, 54], a recent randomized trial in younger adults (18–59 years) has demonstrated that the outcomes of venetoclax‐decitabine induction are non‐inferior to those associated with intensive chemotherapy, with results appearing in favor of venetoclax‐decitabine induction for those aged between 40 and 59 years, and those with adverse‐risk AML, but not for those with RUNX1::RUNX1T1 fusion [32].